Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial
Antikörper-Fine-Specificity korreliert mit Schutz vor Malaria bei dem RTS,S-Impfstoff bei jungen afrikanischen Kindern: Post-hoc-Analyse einer randomisierten Phase-IIb-Studie
PLOS Medicine · 14.05.2026 · 23 (5) · e1004877
DOI: 10.1371/journal.pmed.1004877 ↗Auf einen Blick
Bei 735 Kindern in einer RTS,S-Phase-IIb-Studie war eine starke IgG-Antwort auf NANP2 und J1 mit einem geringeren Risiko für klinische Malaria verbunden. Die Antworten zeigten auch höhere Fc-vermittelte Funktionen.
Fragestellung
Hängt die Spezifität und Kreuzreaktivität von RTS,S-induzierten Antikörpern mit Schutz vor klinischer Malaria zusammen?
Methode
Post-hoc-Analyse einer Phase-IIb-randomisierten kontrollierten Studie mit 735 Kindern im Alter von 1–4 Jahren; zusätzlich präklinische Mausstudien und monoklonale Antikörper-Analysen.
Ergebnisse
Hohe IgG-Antworten auf NANP2 und J1 waren mit geringerem klinischem Malaria-Risiko verbunden: NANP2 aHR 0,838 (95 %-KI 0,716–0,981; p = 0,028), J1 aHR 0,718 (95 %-KI 0,611–0,844; p < 0,001).
Einschränkungen
Nur eine Phase-IIb-Kohorte; die Befunde müssen in weiteren RTS,S- und R21-Kohorten bestätigt werden.
Schlussfolgerung der Autor:innen
Die Befunde liefern neue mögliche Korrelate des Schutzes für RTS,S und neue Hinweise für die Entwicklung von Malaria-Impfstoffen der nächsten Generation.
Kernaussagen
- NANP2- und J1-IgG waren mit geringerem Malaria-Risiko assoziiert
- NANP2: aHR 0,838 (95 %-KI 0,716–0,981)
- J1: aHR 0,718 (95 %-KI 0,611–0,844)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, online erschienen am 14.05.2026. Verfasst von Alessia Hysa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Burnet Institute, Melbourne, Australia. Hauptthemen laut MEDLINE: Malaria Vaccines, Protozoan Proteins, Plasmodium falciparum, Antibodies, Protozoan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Thrasher Research Fund, Cass Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The RTS,S/AS01 malaria vaccine was recently approved for implementation in children, but only provides modest and short-lived efficacy against malaria. RTS,S targets a portion of the Plasmodium falciparum ( Pf ) circumsporozoite protein (CSP), comprising the central NANP-repeat region and C-terminal domain. Mechanisms of immunity and correlates of protection for the RTS,S vaccine are not well defined, hindering progress towards generating highly effective CSP-based vaccines. Methods and findings We investigated epitope specificity and cross-reactivity of vaccine-induced antibodies to six peptides representing CSP epitopes in the N-terminal and central NANP-repeat region. We evaluated antibody reactivity in preclinical mouse vaccine studies, among CSP-specific monoclonal antibodies (mAbs), and in a large RTS,S phase IIb clinical trial in young children 1–4 years old ( n = 735). The preclinical mouse vaccine studies and CSP-specific mAbs were used to initially evaluate IgG responses to the six peptides. Mice immunised with the central NANP-repeat region had IgG with cross-reactivity to an epitope in the N-terminal region. Additionally, we demonstrated that a single CSP-specific mAb could display cross-reactivity to several CSP epitopes. Through post hoc quantification and analysis of antibody responses in the RTS,S phase IIb clinical trial, we found that a subset of children generated IgG with specificity for a short NANP-repeat epitope (NANP 2 ; amino acid sequence: NANPNANP) and cross-reactivity to an N-terminal epitope (J1; amino acid sequence: KQPADGNPDPNANPN). Notably, children with high IgG responses to NANP 2 and J1 had a significantly reduced risk of clinical malaria, compared to children with low responses (IgG to NANP 2 (aHR: 0.838 (95% CI [0.716, 0.981]; p = 0.028)) and J1 (aHR: 0.718 (95% CI [0.611, 0.844]; p < 0.001)), and these responses were also associated with higher antibody Fc-mediated functional activities. We have evaluated NANP 2 and J1 as immunological correlates of protection in one phase IIb cohort, additional studies in other RTS,S and R21 cohorts will be important to further confirm our findings.
Conclusions
These findings reveal promising new correlates of protection for RTS,S and new insights to inform the development of next-generation malaria vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Burnet Institute, Melbourne, Australia.
- Department of Infectious Diseases and Department of Medicine, The University of Melbourne, Melbourne, Australia.
- School of Translational Medicine and Department of Microbiology, Monash University, Melbourne, Australia.
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, England, United Kingdom.
- Astbury Centre for Structural Molecular Biology, School of Molecular & Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
- School of Science, RMIT University, Melbourne, Australia.
ORCID-Profile: Alessia Hysa, Joshua Waterhouse, Sandra Chishimba, Jessica L Horton, Natalie Kingston, David Wetzel, Michael Piontek, Gaoqian Feng, Jahit Sacarlal, Carlota Dobaño, James G Beeson
Förderung
- National Health and Medical Research Council
- Thrasher Research Fund
- Cass Foundation
- Research Training Program Scholarship, Australian Government
- NHMRC for Independent Research Institutes Infrastructure Support Scheme
- Victorian State Government Operational Infrastructure Support
- CERCA Program, Generalitat de Catalunya
- Spanish Agency for International Cooperation and Development
Zitieren
APA
Hysa, A., Opi, D. H., Waterhouse, J., Chishimba, S., Horton, J. L., Kingston, N., Netter, H. J., Wetzel, D., Piontek, M., Feng, G., Sacarlal, J., Dobaño, C., Kurtovic, L., & Beeson, J. G. (2026). Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial. PLOS Medicine, 23(5), e1004877. https://doi.org/10.1371/journal.pmed.1004877
Vancouver
Hysa A, Opi DH, Waterhouse J, Chishimba S, Horton JL, Kingston N, et al. Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial. PLOS Medicine. 2026;23(5):e1004877. doi:10.1371/journal.pmed.1004877
BibTeX
@article{Hysa2026,
author = {Hysa, Alessia and Opi, D Herbert and Waterhouse, Joshua and Chishimba, Sandra and Horton, Jessica L and Kingston, Natalie and Netter, Hans J and Wetzel, David and Piontek, Michael and Feng, Gaoqian and Sacarlal, Jahit and Dobaño, Carlota and Kurtovic, Liriye and Beeson, James G},
title = {Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {5},
pages = {e1004877},
doi = {10.1371/journal.pmed.1004877}
}
EUVIMED